{
    "clinical_study": {
        "@rank": "78993", 
        "arm_group": [
            {
                "arm_group_label": "DRM02", 
                "arm_group_type": "Experimental", 
                "description": "DRM02 Topical Gel, 0.25%"
            }, 
            {
                "arm_group_label": "Vehicle", 
                "arm_group_type": "Placebo Comparator", 
                "description": "DRM02 Topical Gel, Vehicle"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether DRM02 is safe and effective in the\n      treatment of rosacea when applied twice daily for 6 weeks."
        }, 
        "brief_title": "A Safety and Efficacy Study of DRM02 in Subjects With Rosacea", 
        "completion_date": {
            "#text": "March 2014", 
            "@type": "Actual"
        }, 
        "condition": "Rosacea", 
        "condition_browse": {
            "mesh_term": "Rosacea"
        }, 
        "detailed_description": {
            "textblock": "This is a double-blind, randomized, vehicle controlled, study enrolling 30 subjects with\n      rosacea and designed to assess the safety, tolerability, and preliminary efficacy of DRM02.\n\n      Safety will be assessed during the study, through adverse events, local skin responses,\n      urinalysis, serum chemistry and hematology laboratory testing, physical examination and\n      vital signs.\n\n      Preliminary efficacy will be assessed through inflammatory lesion counts, the Investigator's\n      Global Evaluation (IGE) and the Rosacea Signs and Symptoms (RSS) scale."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female 18 to 70 years of age.\n\n          -  Clinical diagnosis of rosacea with a score of 2 or 3 on the Investigator's Global\n             Evaluation (IGE) of Rosacea scale and at least 15 and not more than 40 papules.\n\n          -  Subjects willing to minimize external factors that might trigger rosacea flare-ups.\n\n          -  Male or non-pregnant, non-lactating females.\n\n          -  Signed informed consent.\n\n        Exclusion Criteria:\n\n          -  Severe self-reported facial sensitivity.\n\n          -  Severe sun sensitivity.\n\n          -  Ocular-only, phymatous rosacea or steroid rosacea.\n\n          -  Use of topical rosacea treatments in the 4 weeks prior to baseline.\n\n          -  Use of systemic corticosteroids within the 4 weeks prior to baseline.\n\n          -  Use of systemic antibiotics in the 4 weeks prior to baseline.\n\n          -  Use of systemic retinoids for in the 6 months prior to baseline.\n\n          -  Use of topical retinoids in the 3 months prior to baseline.\n\n          -  Use of light- or laser-based rosacea treatments in the past 2 months prior to\n             baseline.\n\n          -  Cosmetic procedures within the 2 months prior to baseline.\n\n          -  Use of topical anti-aging medications in the 2 weeks prior to baseline.\n\n          -  Subjects who have poor skin condition within 5 cm of the treatment area.\n\n          -  Subjects who are current drug or alcohol abusers; have a history of immunodeficiency\n             or are a poor medical risk because of other systemic diseases or active uncontrolled\n             infections.\n\n          -  Subjects with an unstable medical condition or a medical condition not adequately\n             controlled with standard medical therapy.\n\n          -  Subjects who are actively participating in an experimental therapy study or who have\n             received experimental therapy within 30 days.\n\n          -  Subjects who have a clinically significant laboratory value at screening."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01993446", 
            "org_study_id": "DRM02-ROS02"
        }, 
        "intervention": [
            {
                "arm_group_label": "DRM02", 
                "intervention_name": "DRM02", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Vehicle", 
                "intervention_name": "Vehicle", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 14, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Windsor", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "N8W 5W7"
                    }, 
                    "name": "Windsor Clinical Research, Inc."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Drummondville", 
                        "country": "Canada", 
                        "state": "Quebec", 
                        "zip": "J2B5L4"
                    }, 
                    "name": "Clinique M\u00e9dicale Dr Isabelle Delorme"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Montreal", 
                        "country": "Canada", 
                        "state": "Quebec", 
                        "zip": "H2K 4L5"
                    }, 
                    "name": "Innovaderm Research, Inc"
                }
            }
        ], 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Double-blind, Vehicle Controlled Study of the Safety and Efficacy of Topical DRM02 in Subjects With Rosacea", 
        "other_outcome": {
            "measure": "Rosacea Signs and Symptoms (RSS)", 
            "safety_issue": "No", 
            "time_frame": "From baseline to weeks 0, 1, 2, 3, 4 and 6"
        }, 
        "overall_official": {
            "affiliation": "Dermira, Inc.", 
            "last_name": "Beth Zib", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Canada: Health Canada", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "February 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Change in inflammatory lesion count", 
            "safety_issue": "No", 
            "time_frame": "Week 6"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01993446"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Investigator's Global Evaluation  (IGE)", 
                "safety_issue": "No", 
                "time_frame": "From baseline to weeks 0, 1, 2, 3, 4 and 6"
            }, 
            {
                "measure": "IGE dichotomized into \"success\" and \"failure\"", 
                "safety_issue": "No", 
                "time_frame": "Week 6"
            }, 
            {
                "measure": "Percent change in inflammatory lesions", 
                "safety_issue": "No", 
                "time_frame": "Week 6"
            }
        ], 
        "source": "Dermira, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Dermira, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}